Gratitude, empathy and the tail of the dragon video: www.tiktok.com/t/ZP8NJFyxo/

Legislation like the ORPHAN Cures Act could transform life sciences innovation in 2025, accelerating development for treatments addressing unmet needs. We’re watching these potential tailwinds closely. #LifeSciences #PolicyAndInnovation #healthcarevc #truthinscience

Data & IP will define winners in 2025 in life sciences. Companies with strong clinical data will attract M&A interest, becoming fierce competitors in the life sciences arena. #Innovation #IPStrategy #truthinscience #healthcarevc #lifesciencesvc

The surge in demand for non-prescription products will lead to a rise in unregulated options. Our mission is clear: invest in science-based solutions to protect consumer trust & safety. #Healthcarevc #truthinscience #patientsfirst

With higher drug prices, consumers will turn to nutraceuticals & alternatives. The challenge? Ensuring these options are safe, effective, & science-backed. 2025 could be the year for truth in science to take center stage. #Nutraceuticals #HealthInnovation #truthinscience

Tariffs will lead to rising drug development costs, squeezing R&D budgets at big pharma. As they pull back, R&D will be lead by nimble startups to lead with strong science, innovative solutions & top talent. #DrugDevelopment #HealthcareInnovation #truthinscience

My VC firm has been investing in controlled substances for 5+ years. We see massive opportunities for life sciences innovation in the volatility ahead. Here are 5 trends we’re tracking closely for 2025: tariffs, drug pricing, unregulated products, IP, & legislative tailwinds. #VC #LifeSciences